TITLE

New drugs and dosage forms

PUB. DATE
November 2010
SOURCE
American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on the use of new drugs for specific treatments including dexamethasone intravitreal implant for noninfectious ocular inflammation, combination of drospirenone, ethinyl estradiol, and levomefolate calcium tablets and levomefolate calcium tablets for pre-menstrual dysphoric disorder, and pegloticase injection for intravenous infusion for chronic gout.
ACCESSION #
54607096

 

Related Articles

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p194 

    The article presents the new kinds of drugs and dosage forms including Aliskiren, Moxifloxacin hydrochloride, and Testosterone gel.

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p1974 

    The article offers information related to several drugs and its administration including Bromfenac ophthalmic solution, Lurasidone hydrochloride tablets, and Risedronate Sodium delayed-release tablets.

  • Reexamining the evidence for inpatient glucose control: New recommendations for glycemic targets. Moghissi, Etie S. // American Journal of Health-System Pharmacy;8/15/2010 Supplement, Vol. 67, pS3 

    Purpose. To review the risks of hyperglycemia in hospitalized patients, data supporting the benefits of treating hyperglycemia, and recommendations from the 2009 American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on the management of inpatient...

  • Oral drug approved for relapsing multiple sclerosis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788 

    The article reports on the approval of Novartis AG's fingolimod, a podrug of sphingosine 1-phosphate receptor modulator, for treating patients with relapsing forms of multiple sclerosis by the U.S. Food & Drug Administration (FDA). It looks at how such drug aids in reducing the severity of...

  • FDA approval of colchicine product comes with safety update.  // Reactions Weekly;8/8/2009, Issue 1264, p3 

    The article reports on Colcrys, the first single-ingredient oral colchicine product, approved by the U.S. Food & Drug Administration (FDA) for treatment of acute gout flares and familial Mediterranean fever. The agency identified two uncharacterised safety concerns associated with colchicine...

  • INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;10/25/2010, Vol. 28 Issue 20, p36 

    This section offers news briefs related to the field of ophthalmology as of October 25, 2010. A joint sales marketing agreement to develop and market new and existing products was made by OcuSoft and Ardeo Health. EyeGate Pharmaceuticals and RXi Pharmaceuticals will partner for the ocular...

  • First oral thrombin inhibitor enters market: Drug does not require clinicians to monitor INR. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p1974 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the marketing of dabigatran etexilate or Pradaxa. According to Boehringer Ingelheim Pharmaceuticals Inc., the drug prevents stroke and systematic embolism in patients with nonvalvular atrial fibrillation. It...

  • FDA APPROVES PALIPERIDONE FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA. Cuomo, Amanda // CNS Spectrums: The International Journal of Neuropsychiatric Med;Sep2009, Vol. 14 Issue 9, p464 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on the use of paliperidone palmitate as a maintenance treatment for adult schizophrenia. It cites the starting dose, monthly maintenance dose and dosage range of the drug, as well as its administration in either...

  • FDA APPROVES SUMATRIPTAN INJECTION FOR THE TREATMENT OF MIGRAINES AND CLUSTER HEADACHES. Naccari, Christopher // CNS Spectrums: The International Journal of Neuropsychiatric Med;Sep2009, Vol. 14 Issue 9, p464 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on the use of sumatripan injection as a treatment for acute migraines and cluster headaches. It presents information on the recommended daily dose, administration interval, and abdominal injection precaution of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics